Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alcon ( (CH:ALC) ) just unveiled an announcement.
On August 5, 2025, Alcon announced its agreement to acquire STAAR Surgical, a leader in refractive surgery with Implantable Collamer Lenses, for approximately $1.5 billion. This acquisition is expected to complement Alcon’s laser vision correction business and enhance its ability to offer comprehensive surgical vision correction solutions, especially for high myopes. The transaction, which offers a significant premium on STAAR’s stock price, is anticipated to close within six to 12 months, subject to regulatory and shareholder approvals. The acquisition is expected to be accretive to earnings by the second year, positioning Alcon to accelerate the adoption of STAAR’s innovative EVO ICL technology globally.
The most recent analyst rating on (CH:ALC) stock is a Buy with a CHF84.30 price target. To see the full list of analyst forecasts on Alcon stock, see the CH:ALC Stock Forecast page.
More about Alcon
Alcon is a global leader in eye care, offering a broad portfolio of products aimed at enhancing sight and improving lives. With over 75 years of heritage, Alcon’s Surgical and Vision Care products are used by more than 260 million people across 140 countries, addressing conditions like cataracts, glaucoma, retinal diseases, and refractive errors.
Average Trading Volume: 990,065
Technical Sentiment Signal: Sell
Current Market Cap: CHF35.89B
For detailed information about ALC stock, go to TipRanks’ Stock Analysis page.